- Home
- CRT vs ACHV Comparison
CRT vs ACHV Comparison
Compare CRT & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- ACHV
- Stock Information
- Founded
- CRT 1991
- ACHV N/A
- Country
- CRT United States
- ACHV Canada
- Employees
- CRT N/A
- ACHV N/A
- Industry
- CRT Oil & Gas Production
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CRT Energy
- ACHV Health Care
- Exchange
- CRT Nasdaq
- ACHV Nasdaq
- Market Cap
- CRT 65.1M
- ACHV 72.5M
- IPO Year
- CRT 1992
- ACHV N/A
- Fundamental
- Price
- CRT $10.03
- ACHV $2.35
- Analyst Decision
- CRT
- ACHV Strong Buy
- Analyst Count
- CRT 0
- ACHV 3
- Target Price
- CRT N/A
- ACHV $14.33
- AVG Volume (30 Days)
- CRT 23.9K
- ACHV 178.2K
- Earning Date
- CRT 01-01-0001
- ACHV 05-13-2025
- Dividend Yield
- CRT 8.79%
- ACHV N/A
- EPS Growth
- CRT N/A
- ACHV N/A
- EPS
- CRT 0.95
- ACHV N/A
- Revenue
- CRT $6,623,430.00
- ACHV N/A
- Revenue This Year
- CRT N/A
- ACHV N/A
- Revenue Next Year
- CRT N/A
- ACHV N/A
- P/E Ratio
- CRT $10.66
- ACHV N/A
- Revenue Growth
- CRT N/A
- ACHV N/A
- 52 Week Low
- CRT $8.88
- ACHV $1.84
- 52 Week High
- CRT $14.40
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- CRT 42.20
- ACHV 46.09
- Support Level
- CRT $9.91
- ACHV $2.32
- Resistance Level
- CRT $10.46
- ACHV $2.69
- Average True Range (ATR)
- CRT 0.38
- ACHV 0.18
- MACD
- CRT -0.00
- ACHV 0.02
- Stochastic Oscillator
- CRT 14.85
- ACHV 17.07
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.